LONDON, Sept. 10, 2012 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Drs. Dieter Seitz-Tutter and Alexandra Adams have joined Chiltern, bringing their extensive expertise in clinical research to serve our clients' needs and to strengthen our Global Clinical Development service.
"It gives me great pleasure to announce that Dieter Seitz-Tutter, Ph.D. has been appointed to the new role of Vice President, Global Clinical Development, Europe," stated Aize Smink, Sr. Executive VP, Global Clinical Development, Chiltern. "Dr. Seitz-Tutter will lead Chiltern's Global Clinical Development business across Europe, comprising Clinical Operations and Project Management which is experiencing strong growth thanks to deeper client relations and demand for our quality services."
Recently joining Chiltern is Alexandra Adams, Ph.D. as Director, Late Phase, Europe. "Dr. Adams will lead the Global Late Phase Group in Europe which is focused on implementing tailored solutions for late phase studies and registries in a cost effective way on behalf of our client base," commented Steve Albrecht, Global Head, Late Phase, Chiltern.
Dr. Seitz-Tutter has more than 22 years experience in the clinical research field which he gained from various senior roles in both Pharma and CROs, most recently serving as Vice President Europe with a global corporation. Dr. Seitz-Tutter holds a Master's degree and a doctorate in Biology from the University of Munich, Germany, and is also based out of Munich.
Dr. Adams brings 25 years experience from a varied background in both Pharma and CRO positions. Her experience includes developing new procedures and strategies for the implementation of non-interventional studies. Dr. Adams received her Ph.D. in Biochemistry / Pharmacology from the Cardiothoracic Institute at the University of London. She is a long-standing member of the Institute of Clinical Research, having served on the Board of Directors and in the position of Treasurer. Dr. Adams is based out of Slough, UK.
Company profile
About Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs nearly 1,400 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com.
For More Information Contact:
Natalie Chong |
Susan Ojanen |
|
Marketing Director |
Marketing Executive |
|
Chiltern International Ltd. |
Chiltern International Inc. |
|
171 Bath Road |
1241 Volunteer Parkway |
|
Slough |
Suite 950 |
|
Berkshire SL1 4AA |
Bristol, TN 37620 |
|
UNITED KINGDOM |
USA |
|
Tel: +44 (0) 1753 512 000 |
Tel: +1 (423) 968 9533 |
|
Fax: +44 (0) 1753 511 116 |
Fax: +1 (423) 968 3567 |
|
Email: natalie.chong@chiltern.com |
Email: susan.ojanen@chiltern.com |
|
Share this article